CombinatoRx Drops Arthritis Candidate CRx-150
This article was originally published in The Pink Sheet Daily
Firm will focus efforts on more promising combination, CRx-102, which has shown positive results in Phase II for rheumatoid arthritis and osteoarthritis.
You may also be interested in...
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.